St. Clair Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$949K Hold
39,391
0.24% 48
2026
Q1
$1.11M Buy
39,391
+1,088
+3% +$29K 0.29% 47
2025
Q4
$954K Buy
38,303
+2,250
+6% +$56.7K 0.25% 48
2025
Q3
$919K Buy
36,053
+86
+0.2% +$2.12K 0.24% 47
2025
Q2
$872K Hold
35,967
0.23% 48
2025
Q1
$911K Hold
35,967
0.26% 47
2024
Q4
$954K Hold
35,967
0.27% 46
2024
Q3
$1.04M Hold
35,967
0.3% 44
2024
Q2
$1.01M Hold
35,967
0.32% 43
2024
Q1
$998K Hold
35,967
0.32% 45
2023
Q4
$1.04M Sell
35,967
-600
-2% -$18.1K 0.36% 43
2023
Q3
$1.21M Hold
36,567
0.48% 33
2023
Q2
$1.34M Buy
36,567
+6,246
+21% +$243K 0.52% 31
2023
Q1
$1.24M Buy
30,321
+19,070
+169% +$824K 0.54% 31
2022
Q4
$577K Buy
+11,251
New +$539K 0.36% 33

Other funds holding PFE

St. Clair Advisors's PFE Position: Q2 2026 in Review

St. Clair Advisors held its Pfizer (PFE) position steady in Q2 2026 at 39,391 shares worth $949K. The position accounts for 0.24% of the portfolio, ranked #48.

St. Clair Advisors first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.34M in Q2 2023. 705 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • St. Clair Advisors held 39,391 shares of Pfizer worth $949K as of Q2 2026.
  • St. Clair Advisors left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.24% of St. Clair Advisors's portfolio in Q2 2026, its #48 holding.
  • St. Clair Advisors first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • St. Clair Advisors's Pfizer position peaked at $1.34M in Q2 2023.
  • 705 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on St. Clair Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.